Antibacterial agent discovery using thymidylate synthase biolibrary screening.

Article Details

Citation
Copy to clipboard

Costi MP, Gelain A, Barlocco D, Ghelli S, Soragni F, Reniero F, Rossi T, Ruberto A, Guillou C, Cavazzuti A, Casolari C, Ferrari S

Antibacterial agent discovery using thymidylate synthase biolibrary screening.

J Med Chem. 2006 Oct 5;49(20):5958-68.

PubMed ID
17004711 [ View in PubMed
]
Abstract

Thymidylate synthase (TS, ThyA) catalyzes the reductive methylation of 2'-deoxyuridine 5'-monophosphate to 2'-deoxythymidine 5'-monophosphate, an essential precursor for DNA synthesis. A specific inhibition of this enzyme induces bacterial cell death. As a second round lead optimization design, new 1,2-naphthalein derivatives have been synthesized and tested against a TS-based biolibrary, including human thymidylate synthase (hTS). Docking studies have been performed to rationalize the experimentally observed affinity profiles of 1,2-naphthalein compounds toward Lactobacillus casei TS and hTS. The best TS inhibitors have been tested against a number of clinical isolates of Gram-positive-resistant bacterial strains. Compound 3,3-bis(3,5-dibromo-4-hydroxyphenyl)-1H,3H-naphtho[1,2-c]furan-1-one (5) showed significant antibacterial activity, no in vitro toxicity, and dose-response effects against Staphylococcus epidermidis (MIC=0.5-2.5 microg/mL) clinical isolate strains, which are resistant to at least 17 of the best known antibacterial agents, including vancomycin. So far this compound can be regarded as a leading antibacterial agent.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
10-Propargyl-5,8-Dideazafolic AcidThymidylate synthaseKi (nM)307.420Details